Notícias e Atividades da Amicus Therapeutics

Amicus Therapeutics é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Amicus Therapeutics é uma empresa listada sob o símbolo FOLD (US).

Amicus Therapeutics tem presença direta em 5 países.

Amicus Therapeutics possui 4 subsidiárias incluindo Amicus Therapeutics France, Amicus Therapeutics Germany e Amicus Therapeutics Spain.

Veja o organograma con seus 36 executivos principais

Biografias mais buscadas da Amicus Therapeutics

• Bradley Campbell, President and Chief Executive Officer
• Craig Wheeler, Director
• Margaret McGlynn, Director

Criar um alerta
para seguir os movimentos de executivos da Amicus Therapeutics.

Amicus Therapeutics possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).

Popular M&A news in Biotecnologia

• Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado em 12 de junho de 2025).
• SpliceBio acaba de anunciar uma arrecadação de fundos de 135 milhões de dólares. (publicado em 11 de junho de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships da WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board da Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization da Wheeler Bio

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Amicus Therapeutics

• Amicus Therapeutics to Announce Third Quarter 2020 Financial Results on November 5, 2020 | Amicus Therapeutics
• Amicus Therapeutics Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 49th Annual Meeting of the Child Neurology Society | Amicus Therapeutics
• Amicus Therapeutics Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 49th Annual Meeting of the Child Neurology Society | Amicus Therapeutics
• Amicus Therapeutics Receives European Medicines Agency PRIME Designation for CLN6 Batten Disease Gene Therapy | Amicus Therapeutics
• Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2020 | Amicus Therapeutics
• Amicus Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates | Amicus Therapeutics
• Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference | Amicus Therapeutics
• Amicus Therapeutics to Announce Second Quarter 2020 Financial Results on August 10, 2020 | Amicus Therapeutics
• Amicus Therapeutics Secures $400 Million Non-Dilutive Debt Financing | Amicus Therapeutics
• Amicus Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference | Amicus Therapeutics
• View more press releases Close

Redes sociais sobre Amicus Therapeutics

• Amicus Therapeutics na Wikipedia, Google News e Yahoo Finance
• Amicus Therapeutics na LinkedIn, Twitter e YouTube